+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Research Reports

Proto Oncogene Protein C-akt Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Proto Oncogene Protein C-akt Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
BET Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

BET Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
CDK9 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

CDK9 Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
TIL Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

TIL Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Chronic Myeloid Leukemia - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Myeloid Leukemia - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
Thymic Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Thymic Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Cutaneous Squamous Cell Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Cutaneous Squamous Cell Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 120 Pages
  • Global
From
Hepatocellular Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatocellular Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 230 Pages
  • Global
From
HER2 Positive Breast Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

HER2 Positive Breast Cancer- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
HER2 Negative Breast Cancer- Pipeline Insight, 2025 - Product Thumbnail Image

HER2 Negative Breast Cancer- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
Marginal Zone Lymphoma - Pipeline Insight, 2025 - Product Thumbnail Image

Marginal Zone Lymphoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 150 Pages
  • Global
From
Primary Mediastinal Large B-Cell Lymphoma - Pipeline Insight, 2025 - Product Thumbnail Image

Primary Mediastinal Large B-Cell Lymphoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 120 Pages
  • Global
From
Lung Adenocarcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Lung Adenocarcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
Head And Neck Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025 - Product Thumbnail Image

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 450 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chemotherapy-induced Thrombocytopenia (CIT) - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy-induced Thrombocytopenia (CIT) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more